Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TEV-295
- Development stage
- Unknown
- Lead developer
- Teva Pharmaceutical
- Administration
- Subcutaneous, Intravenous
01
Overview
TEV-295 is a preclinical biosimilar candidate being developed by Teva Pharmaceuticals in collaboration with Alvotech. It is part of an expanded strategic partnership between the two companies, established in July 2023, to develop and commercialize biosimilar medicines for the U.S. market. While the specific biological target of TEV-295 remains confidential in public pipeline disclosures, it is categorized within Teva's biosimilar portfolio, which focuses on therapeutic areas such as oncology, immunology, ophthalmology, and hematology. As a biosimilar, TEV-295 is intended to be a highly similar version of an existing reference biologic, designed to provide a more affordable treatment option while maintaining comparable safety and efficacy.
- Other names
- TEV-295-Teva-biosimilarTEV295-Teva-biosimilarTEV 295-Teva-biosimilar
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on TEV-295.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TEV-295.